StockDocs
Project by Matthew Castle Please send feedback to matthewgcastle@gmail.com
CELU

Celularity Inc.

CELUW Nasdaq Pharmaceutical Preparations EDGAR ↗
$0.00

Key statistics

from XBRL data in SEC filings
Market cap
$57.9K
Revenue (TTM)
$26.6M
Net income (TTM)
-$91.7M
EPS (TTM)
$-3.59
P/E ratio
Dividend yield
Free cash flow
-$13.4M
Cash
$6.17M
Total assets
$107M
Gross margin
25.4%
52-week range

Recent SEC filings

40 most recent
Annual, quarterly & current reports
8-K Delisting notice or listing-rule failure Jul 29, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Director or officer change Jun 30, 2026 8-K Director or officer change Jun 25, 2026 8-K Delisting notice or listing-rule failure Jun 12, 2026 8-K Director or officer change; Regulation FD disclosure Jun 3, 2026 8-K Entered a material agreement; Took on a direct financial obligation May 28, 2026 10-K Fiscal year ended 2025-12-31 Apr 30, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Modified rights of security holders; Director or officer change; Other events Apr 21, 2026 8-K Entered a material agreement; Other events Mar 10, 2026 8-K Director or officer change Mar 5, 2026 8-K Director or officer change Jan 21, 2026 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity; Other events Dec 23, 2025 8-K Shareholder vote results Dec 19, 2025 8-K Other events Dec 5, 2025 10-Q Quarter ended 2025-09-30 Nov 14, 2025 8-K Entered a material agreement; Unregistered sale of equity; Amended charter or bylaws Oct 28, 2025 8-K Other events Sep 3, 2025 10-Q Quarter ended 2025-06-30 Aug 29, 2025 10-Q Quarter ended 2025-03-31 Aug 29, 2025 8-K Entered a material agreement; Other events Aug 18, 2025 8-K Entered a material agreement; Other events Aug 12, 2025 8-K Entered a material agreement; Took on a direct financial obligation; Unregistered sale of equity Aug 1, 2025 8-K Entered a material agreement; Unregistered sale of equity Jul 30, 2025 8-K/A Jul 29, 2025 8-K Entered a material agreement; Unregistered sale of equity Jul 22, 2025 8-K Director or officer change Jun 10, 2025 8-K Director or officer change Jun 6, 2025 10-K/A Fiscal year ended 2024-12-31 May 21, 2025 8-K Entered a material agreement; Unregistered sale of equity May 20, 2025 8-K Director or officer change May 16, 2025 8-K Results of operations (earnings release) May 9, 2025 10-K Fiscal year ended 2024-12-31 May 8, 2025 8-K Other events May 1, 2025 8-K Delisting notice or listing-rule failure Apr 23, 2025 8-K Entered a material agreement; Unregistered sale of equity Mar 21, 2025 8-K Other events Feb 24, 2025 8-K Entered a material agreement; Unregistered sale of equity Feb 18, 2025 8-K Entered a material agreement Jan 27, 2025 8-K Terminated a material agreement Jan 24, 2025 8-K Entered a material agreement; Unregistered sale of equity Jan 3, 2025